APA

Müller H. J., Grubert M., Hilger R., Richly H., Port R., Scheulen M. & Mross K. (20030502). The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin--a population based pharmacokinetic study of CESAR-APOH. Central European Society for Anticancer Drug Research. Working Group for Pharmacology in Oncology and Hematology. : International journal of clinical pharmacology and therapeutics.

Chicago

Müller H J, Grubert M, Hilger R, Richly H, Port R, Scheulen M and Mross K. 20030502. The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin--a population based pharmacokinetic study of CESAR-APOH. Central European Society for Anticancer Drug Research. Working Group for Pharmacology in Oncology and Hematology. : International journal of clinical pharmacology and therapeutics.

Harvard

Müller H. J., Grubert M., Hilger R., Richly H., Port R., Scheulen M. and Mross K. (20030502). The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin--a population based pharmacokinetic study of CESAR-APOH. Central European Society for Anticancer Drug Research. Working Group for Pharmacology in Oncology and Hematology. : International journal of clinical pharmacology and therapeutics.

MLA

Müller H J, Grubert M, Hilger R, Richly H, Port R, Scheulen M and Mross K. The influence of elevated liver function parameters on the pharmacokinetics of doxorubicin and epirubicin--a population based pharmacokinetic study of CESAR-APOH. Central European Society for Anticancer Drug Research. Working Group for Pharmacology in Oncology and Hematology. : International journal of clinical pharmacology and therapeutics. 20030502.